Over time, systemic lupus erythematosus (SLE) can lead to considerable organ damage. Preventing this outcome is complicated by a scarcity of treatment options that can drive the disease into remission and by the side effects of existing therapies, such as prednisone and other corticosteroids, which may themselves contribute to the long-term damage. The largest study…
Imagine telling a patient “You’re in remission!” and finding out it’s not true. The last thing you want to do is get it wrong clinically and put your patient on an emotional rollercoaster. With large vessel vasculitis (LVV) in particular, physicians struggle to be accurate, to determine if indeed the disease has gone away or…
NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…
A new study examined the independent effects of excess weight and obesity on achieving sustained remission in rheumatoid arthritis (RA) patients. Researchers found that within three years of RA diagnosis, overweight and obese patients were significantly less likely to achieve sustained remission than patients with healthy body mass indices (BMIs). Higher BMIs were also associated with persistent disease activity…
NEW YORK (Reuters Health)—Obesity in women and current smoking in men appear to be the strongest predictors of lack of remission in early rheumatoid arthritis (RA) within one year, according to new research presented June 13 at EULAR 2018, the annual meeting of the European League Against Rheumatism, in Amsterdam.1 Even though early identification and…
SAN DIEGO—Treatment strategies for systemic lupus erythematosus (SLE) have changed a great deal over the years, but progress has been slow and inadequate. According to a 2011 survey, many patients with lupus still report that they have a low quality of life due to their health problems.1 Rheumatologists face the challenge to develop more successful…
In a recent clinical trial, tocilizumab helped sustain glucocorticoid-free remission in patients with giant cell arteritis. Patients also received a prednisone taper, and 50% of tocilizumab-treated patients achieved prednisone-free remission and were less likely to experience disease flare compared with placebo…
A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…
WASHINGTON, D.C.—Clinical aspects of managing patients with rheumatoid arthritis (RA) in remission were discussed by a panel of experts at the 2016 ACR/ARHP Annual Meeting during the session titled Rheumatoid Arthritis—Clinical Aspects IV: Managing Patients in Remission. Among the issues raised were strategies to taper or discontinue biologic therapies, as well as clinical predictors of…
NEW YORK (Reuters Health)—After starting biologic therapy for rheumatoid arthritis (RA), patients with higher disease activity at baseline achieved greater improvements in measures of disease activity than those with lower levels of disease, but they were less likely to achieve remission or even low disease activity, according to a new real world analysis of registry data….